期刊文献+

耐碳青霉烯类肠杆菌科细菌临床分布特点及危险因素分析 被引量:4

Analysis of clinical characteristics and risk factors in Carbapenem-resistant Enterobacteriaceae infection
原文传递
导出
摘要 目的分析我院耐碳青霉烯类肠杆菌科细菌(Carbapenem-resistant Enterobacteriaceae,CRE)临床分布特点和危险因素。方法回顾性分析哈尔滨医科大学附属第二医院2017年1月~2019年12月期间293例CRE感染患者的临床资料,以同期293例碳青霉烯类敏感的肠杆菌科细菌(Carbapenem-sensitive Enterobacteriaceae,CSE)感染患者作为对照组,采用单因素分析比较两组间差异,Logistic多因素分析CRE感染发生的独立危险因素。结果CRE检出率为2.08%(293/14086),主要检出菌株为肺炎克雷伯菌46.08%(135/293),其次是大肠埃希菌19.80%(58/293)、阴沟肠杆菌13.65%(40/293);呼吸道标本中CRE检出率最高41.64%(122/293),其次是泌尿道、各种穿刺液和外周血,分别为19.80%(58/293)、18.77%(55/293)和14.68%(43/293);主要检出科室是ICU占20.14%(59/293),其次是泌外科、普外科均为11.60%(34/293),神经外科为11.26%(33/293);多因素Logistic分析发现,胸腔穿刺(OR=2.956,95%CI:1.295~6.745,P=0.010)和之前使用过替加环素(OR=2.246,95%CI:1.071~4.712,P=0.032)为CRE感染的独立危险因素。结论我院CRE感染主要菌株是肺炎克雷伯菌和大肠埃希菌;胸腔穿刺和之前使用过替加环素是我院CRE感染的独立危险因素。 Objective To analyze the clinical characteristics and risk factors of Carbapenem-resistant Enterobacteriaceae(CRE)infection in our hospital,so as to provide a strong basis for preventing and controling CRE infection.Methods The histories of 293 non repetitive patients with CRE infection from January 2017 to December 2019 in the Second Affiliated Hospital of Harbin Medical University were retrospectively analyzed,and 293 cases of Carbapenem-sensitive Enterobacteriaceae(CSE)infection in the same period were selected as the control group.The differences between the two groups were compared by univariate analysis,and the independent risk factors of CRE infection were analyzed by logistic multivariate analysis.Results The overall CRE infection incidence was 2.08%(293/14086).The CRE isolates mainly were Klebsiella pneumoniae 46.08%(135/293),followed by Escherichia coli 19.80%(58/293)and Enterobacter cloacae 13.65%(40/293);CRE were mainly isolated from respiratory tract 41.64%(122/293),followed by urinary tracts,sterile body fluids of various parts and peripheral blood culture which were 19.80%(58/293),18.77%(55/293)and 14.68%(43/293),respectively;the isolation rate of CRE in the department of ICU was 20.14%(59/293),department of urology and general surgery was each 11.60%(34/293),and department of neurosurgery was 11.26%(33/293);Multivariate analysis showed that thoracentesis(OR=2.956,95%CI:1.295~6.745,P=0.010)and previous use of tigecycline(OR=2.246,95%CI:1.071~4.712,P=0.032)were independent risk factors for CRE infection.Conclusion CRE isolates mainly are Klebsiella pneumoniae and Escherichia coli;thoracentesis and previous use of tigecycline therapy are independent risk factors of CRE infection in our hospital.
作者 周南竹 陈复辉 ZHOU Nan-zhu;CHEN Fu-hui(Department of Respiratory and Critical Care Medicine,The Second Affiliated Hospital of Harbin Medical University,Harbin 150081,China)
出处 《哈尔滨医科大学学报》 CAS 2021年第5期484-489,共6页 Journal of Harbin Medical University
基金 国家科技部十三五科技重大专项基金资助项目(2017ZX10103004)。
关键词 耐碳青霉烯类肠杆菌科细菌 临床特征 危险因素 Carbapenem-resistant Enterobacteriaceae clinical characteristics risk factors
  • 相关文献

参考文献8

二级参考文献68

  • 1Nagaraj S,Chandran SP,Shamanna P,et al.Carbapenem resistance among Escherichia coli and Klebsiella pneumoniae in a tertiary care hospital in south India[J].Indian J Med Microbiol,2012,30(1):93-95.
  • 2Nordmann P,Dortet L,Poirel L.Carbapenem resistance in Enterobacteriaceae:here is the storm[J].Trends Mol Med,2012,18(5):263-272.
  • 3Pano Pardo JR,Serrano Villar S,et al.Infections caused by carbapenemase-producing Enterobacteriaceae:risk factors,clinical features and prognosis[J].Enferm Infecc Microbiol Clin,2014,32(Suppl 4):S41-48.
  • 4CLSI.Performance standards for antimicrobial susceptibility testing;twenty-second informational supplement[S].M100-S22.CLSI,2012.
  • 5CDC.Guidance for control of carbapenem-resistant Enterobacteriaceae(CRE)[S].CDC,2012.
  • 6Shilo S,Assous MV,Lachish T,et al.Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality:a case-control study[J].Infection,2013,41(2):503-509.
  • 7Daly MW,Riddle DJ,Ledeboer NA,et al.Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae[J].Pharmacotherapy,2007,27(7):1052-1057.
  • 8Falagas ME,Lourida P,Poulikakos P,et al.Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae:systematic evaluation of the available evidence[J].Antimicrob Agents Chemother,2014,58(2):654-663.
  • 9Oliva A,D′Abramo A,D′Agostino C,et al.Synergistic activity and effectiveness of a double-carbapenem regimen in pandrugresistant Klebsiella pneumoniae bloodstream infections[J].J Antimicrob Chemother,2014,69(6):1718-1720.
  • 10Qi Y,Wei Z,Ji S,et al.ST11,the dominant clone of KPCproducing Klebsiella pneumoniae in China[J].J Antimicrob Chemother,2011,66(2):307-312.

共引文献93

同被引文献42

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部